Innoviva Future Growth

NasdaqGS:INVA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	359	N/A	N/A	N/A	1
12/31/2025	334	N/A	N/A	N/A	1
12/31/2024	301	N/A	N/A	N/A	1
12/31/2023	310	180	141	141	N/A
9/30/2023	290	50	116	117	N/A
6/30/2023	290	233	88	88	N/A
3/31/2023	318	233	129	129	N/A
12/31/2022	331	214	202	202	N/A
9/30/2022	373	293	291	291	N/A
6/30/2022	404	99	372	372	N/A
3/31/2022	396	188	378	378	N/A
12/31/2021	392	266	364	364	N/A
9/30/2021	375	309	351	351	N/A
6/30/2021	365	265	329	329	N/A
3/31/2021	344	253	324	324	N/A
12/31/2020	337	224	313	313	N/A
9/30/2020	322	216	295	295	N/A
6/30/2020	299	228	278	278	N/A
3/31/2020	285	189	254	254	N/A
12/31/2019	261	157	257	257	N/A
9/30/2019	265	375	252	252	N/A
6/30/2019	261	382	255	255	N/A
3/31/2019	264	399	250	250	N/A
12/31/2018	261	395	224	224	N/A
9/30/2018	251	190	210	210	N/A
6/30/2018	238	166	193	193	N/A
3/31/2018	229	147	164	164	N/A
12/31/2017	217	134	142	142	N/A
9/30/2017	191	101	N/A	115	N/A
6/30/2017	176	92	N/A	92	N/A
3/31/2017	150	72	N/A	81	N/A
12/31/2016	134	60	N/A	61	N/A
9/30/2016	113	38	N/A	47	N/A
6/30/2016	93	19	N/A	29	N/A
3/31/2016	71	-4	N/A	19	N/A
12/31/2015	54	-19	N/A	10	N/A
9/30/2015	38	-39	N/A	-1	N/A
6/30/2015	26	-56	N/A	-25	N/A
3/31/2015	16	-68	N/A	-82	N/A
12/31/2014	8	-74	N/A	-131	N/A
9/30/2014	3	-66	N/A	-166	N/A
6/30/2014	2	-55	N/A	-186	N/A
3/31/2014	2	-9	N/A	-149	N/A
12/31/2013	5	-31	N/A	-130	N/A
9/30/2013	9	-53	N/A	-114	N/A
6/30/2013	10	-78	N/A	-100	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if INVA's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if INVA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if INVA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: INVA's revenue (5.5% per year) is forecast to grow slower than the US market (8% per year).

High Growth Revenue: INVA's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INVA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Innoviva Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 23% to US$13.00

Price target decreased by 12% to US$15.17

Price target decreased to US$18.67

Price target increased to US$20.50

Recent updates

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

New 90-day high: US$12.51

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Investor sentiment improved over the past week

New 90-day high: US$11.81

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders

Third quarter earnings released

Innoviva reports Q3 results

New 90-day low: US$9.99

New 90-day low: US$10.85

New 90-day low - US$12.73

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies